Highlights Molecular Partners AG Nasdaq

Equities

MOLN

US60853G1067

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
6.53 ^USD	-1.36%		-9.68%	+56.22%

Jun. 20	Top Premarket Gainers	MT
Jun. 17	Transcript : Molecular Partners AG Presents at TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit, Jun-17-2024 10:40 AM

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top Premarket Gainers	Jun. 20	MT
Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...	Jun. 14
Top Premarket Gainers	Jun. 14	MT
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024	Jun. 14	CI
Top Premarket Gainers	Jun. 12	MT
Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy Candidate MP0712, Targeting DLL3	Jun. 11	CI
Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024	Jun. 01	CI
Molecular Partners AG Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action	Apr. 29	CI
Molecular Partners Swings to Loss in FY23; Revenue Down	Mar. 15	MT
Molecular Partners AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
US Court Dismisses Putative Class Action Against Molecular Partners	Mar. 03	MT
Molecular Partners, Orano Med Team Up to Develop Radio-DARPin Therapeutics Against Cancer	Jan. 08	MT
Molecular Partners AG and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	Jan. 05	CI
Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting	Dec. 10	CI
Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting	Nov. 03	CI
Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition	Nov. 02	CI
Molecular Partners AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Molecular Partners Turns to Loss in H1; Revenue Slides Down	23-08-24	MT
Molecular Partners AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Molecular Partners AG Nasdaq

Equities

MOLN

US60853G1067

Highlights

Filters